

Beslut vid Fru Berta Kamprads styrelsemöte 15 maj 2024

Gabriel Adrian FBKS-2024-37

Novel pre-clinical models to investigate FLASH from curative tumor efficacy by electrons & protons to principal DNA-damage assessment
Anslag beviljat: 2025-2026

Mohamed Altai FBKS-2024-15

Unraveling the Potential of LRRRC15-Targeted radiotheranostics: A Translational Investigation.
Anslag beviljat: 2025-2026

Cristian Bellodi FBKS-2024-24

Harnessing the RNA Epitranscriptomic Code in Triple-Negative Breast Cancer: Novel Diagnostic and Therapeutic Opportunities
Anslag beviljat: 2025-2027

Mattias Belting FBKS-2024-26

Translational studies in neuro-oncology integrating focused ultrasound with new therapeutic modalities in glioma
Anslag beviljat: 2025-2028

Ylva Bengtsson FBKS-2024-27

Trace elements and mammographic features: Selenium, iodine and thyroid hormones in relation to mammographic density, mammographic tumor appearance and mode of detection
Anslag beviljat: 2025

David Borg FBKS-2024-1

Definitive immuno-oncology in resectable dMMRMSI-H gastric and esophageal adenocarcinoma (DIORAMA phase II study)
Anslag beviljat: 2025-2026

Ana Carneiro FBKS-2024-13

MyTrial.Finder - A platform for better cancer treatments
Anslag beviljat: 2025-2027

Crister Ceberg FBKS-2024-23

Translational image-guided radiotherapy at the XenX facility
Anslag beviljat: 2025-2026

Yvonne Ceder FBKS-2024-9

Epitranscriptomics in prostate cancer progression
Anslag beviljat: 2025-2027

Mats Ehinger FBKS-2024-32

Kill histomorphology for lymphoma diagnosis
Anslag beviljat: 2025-2026

Henrik Ekedahl FBKS-2024-12

The effects of sun exposure and pigmentation phenotype on prognosis and response to treatment in metastatic malignant melanoma
Anslag beviljat: 2025-2026

Lennart Greiff FBKS-2024-20

Stratification by immune profiles to immune-checkpoint-inhibition in patients with head and neck cancer: exploring the subgroups of EBV+ nasopharyngeal- and HPV+ oropharyngeal cancer
Anslag beviljat: 2025-2027

Anna Hagström FBKS-2024-28

Dissect the role of somatic mutations on gene expression patterns to uncover mechanisms of treatment resistance
Anslag beviljat: 2025-2026

Göran Jönsson FBKS-2024-29

Equipment for single cell spatial analysis of tumors at Lund University Cancer Center
Anslag beviljat: 2025

Anna-Maria Larsson FBKS-2024-10

Towards improved prognostication and treatment monitoring in metastatic breast cancer by deciphering the immune landscape
Anslag beviljat: 2025-2026

Johan Linderöth FBKS-2024-21)

Genetic predisposition for developing cardiac late side effects after mediastinal radiotherapy of Hodgkins lymphoma with focus on radiobiological studies of SETD7
A Swedish Hodgkin Lymphoma Group Study
Anslag beviljat: 2025-2026

Michael Ljungberg FBKS-2024-31

Radionuclide Therapy Dosimetry, based on Quantitative SPECTCT: Development of a Reference Image Database for use in Clinical Trials and Multi-Center comparisons
Anslag beviljat: 2025-2028

Johan Malm FBKS-2024-19

Biobank Empowering Cutting-Edge Clinical Research in Lund
Anslag beviljat: 2025-2027

Christel Nielsen FBKS-2024-38

Think before you ink? Tattoos as a risk factor for liver and bladder cancer
Anslag beviljat: 2025-2026

Martin Nilsson FBKS-2024-17

Prospective evaluation of individualized radiotherapy for anal cancer patients
Anslag beviljat: 2025-2026

Pontus Nordenfelt FBKS-2024-8

Spatiotemporal multiplexed imaging of migrating cancer cells at high fidelity using correlative data-driven microscopy
Anslag beviljat: 2025-2026

Helena Nyström FBKS-2024-33

PERELI- A phase 2, open label study of PEmigatinib and REtifaxlimab in advanced dedifferentiated Lliposarcoma
Anslag beviljat: 2025-2026

Mats Ohlin FBKS-2024-30

OptiCAR development of Chimeric Antigen Receptors for use in cancer treatment
Anslag beviljat: 2025-2027

Lars E. Olsson FBKS-2024-4

Pioneering MRI Imaging Biomarkers for Tailored Radiotherapy

Anslag beviljat: 2025-2026

Astrid Persson FBKS-2024-22

Increasing the understanding of adverse effects after ultra-hypofractionated radiotherapy for localised prostate cancer

Anslag beviljat: 2025

Kristian Pietras FBKS-2024-25

Targeting cancer-associated fibroblasts in triple negative breast cancer: from basic science to clinical trial

Anslag beviljat: 2025-2026

Charlotte Rolny FBKS-2024-35

Unlocking the Prognostic and Mechanistic Potential of Tumor-Associated Macrophages

Anslag beviljat: 2025-2027

Mikael Segerlantz FBKS-2024-3

Comprehensive Palliative Care: Person-Centered Treatment for Patients with Advanced Cancer Diseases

Anslag beviljat: 2025-2026

Katarina Sjögren Gleisner FBKS-2024-7 -

Dosimetry-guided molecular radiotherapy with alpha- and beta-emitting radionuclides - tumour efficacy and risks of toxicity

Anslag beviljat: 2025-2027

Johan Staaf FBKS-2024-14

The tumor genotype and immune phenotype as markers for response and treatment resistance in primary triple negative breast cancer

Anslag beviljat: 2025-2027

Anders Wittrup FBKS-2024-36

Rational development of deep tumor tissue RNA delivery

Anslag beviljat: 2025-2026

Nils-Bjarne Woods FBKS-2024-34

Hyper-Targeting Pluripotent Stem Cell Derived Natural Killer Cells for Adoptive Cell Immunotherapy for Lymphoma

Anslag beviljat: 2025-2027

Anders Örbom FBKS-2024-6)

Preclinical investigation of novel synergistic combination therapies against metastatic castration-resistant prostate cancer

Anslag beviljat: 2025